| Neutrophil count | Lymphocyte count | NLR | ||||||
---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | |
Overall nadir (n = 196) | |||||||||
 Overall survival | 1.27 | 1.09–1.47 | <0.01 | 1.60 | 0.93–2.76 | 0.09 | 1.01 | 0.98–1.05 | 0.51 |
 Cancer-specific survival | 1.14 | 0.99–1.31 | 0.07 | 0.86 | 0.45–1.62 | 0.63 | 1.01 | 0.98–1.04 | 0.50 |
 Local control | 1.23 | 1.04–1.46 | 0.02 | 1.53 | 0.83–2.83 | 0.18 | 1.00 | 0.95–1.05 | 0.92 |
 Distant control | 1.18 | 0.95–1.49 | 0.14 | 0.38 | 0.08–1.75 | 0.21 | 1.05 | 1.01–1.10 | 0.01 |
Pre treatment (n = 194) | |||||||||
 Overall survival | 1.21 | 1.02–1.44 | 0.03 | 1.03 | 0.68–1.55 | 0.89 | 1.07 | 1.01–1.14 | 0.02 |
 Cancer-specific survival | 1.22 | 1.05–1.41 | <0.01 | 1.18 | 0.85–1.63 | 0.33 | 1.04 | 0.98–1.11 | 0.17 |
 Local control | 1.16 | 0.95–1.42 | 0.15 | 1.41 | 0.97–2.05 | 0.07 | 1.05 | 0.96–1.14 | 0.31 |
 Distant control | 1.37 | 1.09–1.47 | <0.01 | 1.45 | 0.95–2.21 | 0.09 | 1.00 | 0.89–1.13 | 1.00 |
Post treatment (n = 136) | |||||||||
 Overall survival | 1.29 | 1.06–1.56 | 0.01 | 1.10 | 0.36–3.35 | 0.87 | 1.03 | 0.98–1.08 | 0.31 |
 Cancer-specific survival | 1.25 | 0.99–1.57 | 0.06 | 0.47 | 0.12–1.89 | 0.29 | 1.04 | 0.99–1.10 | 0.10 |
 Local control | 1.47 | 1.16–1.86 | <0.01 | 1.42 | 0.39–5.12 | 0.60 | 1.04 | 0.99–1.09 | 0.17 |
 Distant control | 1.18 | 0.88–1.57 | 0.27 | 1.65 | 0.47–5.81 | 0.44 | 0.98 | 0.91–1.06 | 0.67 |